• Profile
Close

Monosomy 17 in potentially curable HER2 -amplified breast cancer: Prognostic and predictive impact

Breast Cancer Research and Treatment Oct 12, 2017

Page DB, et al. - This work aimed to retrospectively identify HER2-amplified, stage I–III breast cancers with monosomy of chromosome 17 (m17) and characterize the impact of trastuzumab treatment. In this study, patients with HER2-amplified m17 cancers treated with trastuzumab indicated outcomes comparable to patients from the large phase III adjuvant trastuzumab trials who were HER2-positive. Findings thereby supported the critical role of HER2-directed therapy in this patient population.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay